Aurinia Pharmaceuticals Inc (AUPH)

Aurinia Pharmaceuticals Inc (AUPH)


Charts by TradingView

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

Aurinia Pharmaceuticals Inc (AUPH) Profile

Aurinia Pharmaceuticals Inc (AUPH.xnas) is a late-stage clinical biopharmaceutical company headquartered in Victoria, British Columbia, Canada. Aurinia is developing and commercialising therapies to treat targeted patient populations with serious diseases with high unmet medical needs. The company employs 294 people, has a US commercial hub in Rockville and Maryland, and extends to other global areas. The Aurinia Pharmaceuticals Inc stock is listed on the NASDAQ and had a market capitalisation of $2.41B (USD) as of January 2022. In December 2020, Aurinia Pharmaceuticals and Otsuka Pharmaceuticals entered a collaboration and licensing agreement to develop and commercial oral voclosporin as a treatment for Lupus nephritis (LN) in the European Union, Japan, United Kingdom, and Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein, and Ukraine. Aurinia Pharmaceuticals announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS (voclosporin) for the treatment of adults with active lupus nephritis. The LUPKYNIS is the first and only approved medicine from FDA with 3 years of pivotal trial results, including long-term safety data, within LN.

Holding cost
Long
-5%
Short
-2.5%
Trading hours in US Eastern Time
Fri
16:30-23:00
Mon
16:30-23:00
Tue
16:30-23:00
Wed
16:30-23:00
Thu
16:30-23:00
Sun
Closed
Sat
Closed

Start Trading Aurinia Pharmaceuticals Inc (AUPH)
with a Market Leader Today

Share CFD Trading FAQ

Each investor owning shares of a company is also owning fragments of the company. A quite simple way to explain what a stock is is basically when a company divides itself into several shares and then it makes a part of these equities available to the public, at a price. Each investor owning shares of a company is owning fragments of the company.

While shares represent units of ownership within a company Contracts for Difference (CFDs) allow traders to speculate on the future share price fluctuations of an underlying asset. Thus when trading CFDs traders do not physically own the underlying asset. CFDs are available for a range of underlying assets, such as shares, commodities, and foreign exchange, and indices.

6 Reasons to Trade Share
CFDs with FP Markets

An Australian-regulated
forex & CFD broker

Go Long or Short

Increase your ability to profit in all market conditions Leverage options up to 20:1

Direct Market Access (DMA) Execution

Real-time, transparent share prices Control, Functionality and deep liquidity Full Market depth & see your orders in the queue

Advanced Platforms
& Technology

MT4, MT5, Webtrader & Iress with superior client portal

24/5 Multilingual
Customer Support

Award winning support & personal account managers

Global Exposure

Low margins and competitive commission +10,000 products on global stocks across 4 continents

Earn Dividends

On long positions No ownership of physical shares necessary

Start Trading
in Minutes

Open an account now

bullet Access 10,000+ financial instruments
bullet Auto open & close positions
bullet News & economic calendar
bullet Technical indicators & charts
bullet Many more tools included

By supplying your email you agree to FP Markets privacy policy and receive future marketing materials from FP Markets. You can unsubscribe at any time.





Get instant Updates in Telegram
Sitemap | © FP Markets 2022